Abstract: Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjutant.

Abstract: Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.

Abstract: Provided in the present invention is the use of a mevalonic acid pathway inhibitor in the preparation of a drug for treating and/or preventing tumours, inducing immunogenic death of tumour cells, inducing immune responses and activating T cells or DC cells to directly promote host immunity. Also provided in the present invention is a pharmaceutical composition comprising the mevalonic acid pathway inhibitor and an antitumour drug (for example, an immune checkpoint inhibitor and any drug that can lead to new antigen production) and a combination of the mevalonic acid pathway inhibitor and an antitumour drug (for example, an immune checkpoint inhibitor and any drug that can lead to new antigen production) and/or the radiotherapy.

Abstract: Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate to pathway as an adjuvant.

Abstract: The present invention relates to use of mast cell carboxypeptidase as a marker for anaphylaxis or mastocytosis in serum, plasma or saliva samples. Detection of elevated mast cell caroboxypeptidase in for example serum samples is proposed for reducing false negatives in relation to diagnosis of anaphylaxis and various categories of mastocytosis by picking up serum tryptase-negative cases.